Cancer of the nasopharynx in Aotearoa New Zealand from 1994 to 2018: Incidence and survival in a population-based, national registry cohort study

Alice Minhinnick,a,b* Phyu Sin Aye,b J Mark Elwood,b and Mark James McKeagea,b

aAuckland City Hospital, Auckland, New Zealand
bUniversity of Auckland, Auckland, New Zealand

Summary

Background Cancer of the nasopharynx has remarkable geographic and ethnic variation in incidence and outcomes globally. Recent advances in diagnostic and therapeutic technologies provide new opportunities for early detection and improved outcomes. This study aimed to determine the incidence, demographics, outcomes and time trends of cancer of the nasopharynx in Aotearoa New Zealand over the last 25 years.

Methods In a population-based, national registry cohort study of notifications of malignant neoplasms of the nasopharynx made to the New Zealand Cancer Registry between 1994 and 2018, age-specific and age-standardised incidence rates and survival outcomes were evaluated.

Findings 577 registrations of nasopharyngeal cancer from between 1994 and 2018 were analysed; median age at diagnosis 54 years; 72.4% male; 37.4% Asian, 24.3% New Zealand European, 25.3% Pacific peoples, 13.0% Māori.

Age-standardised annual incidence remained low (<1/100,000 person-years) and stable from 1994 to 2018. Age-standardised incidence rates in Pacific peoples, Asian and Māori were 21 (95% CI 12.07-35.21)-, 17 (10.95-25.33)- and 4 (2.79-7.07)-fold higher, respectively, than New Zealand Europeans. Epstein-Barr virus-related morphologies predominated keratinising squamous cell carcinoma and not-otherwise-specified morphological subtypes. Ten-year overall survival rate for the cohort was 49.2% (95% CI 44.7-53.5). Older age at diagnosis (65−94 years), Māori or Pacific ethnicity, keratinising squamous cell carcinoma and distant disease were associated with shorter overall survival, whereas younger age at diagnosis (10-29 years), and Asian ethnicity were associated with longer survival.

Interpretation Aotearoa New Zealand has a distinct profile of nasopharyngeal cancer, with age, ethnicity and morphology among the main determinants of incidence and survival.

Funding None.
Research in context

Evidence before this study

International evidence describes a distinct geographic and ethnic variation in nasopharyngeal cancer epidemiology. There are few published studies on the epidemiology of nasopharyngeal cancer in Aotearoa New Zealand. We searched PubMed and Scopus from inception to 2021 with terms defined as “New Zealand” AND “nasopharyngeal” AND (“epidemiology” OR “incidence” OR “survival”). Three relevant articles were identified. One study reported nasopharyngeal cancer incidence over the period 1954-1991 but did not describe the cohort’s demographic or clinical characteristics. The two other studies were limited to the Auckland region. One of these reported that from 1976-1985 nasopharyngeal cancers disproportionally affected Maori, Pacific and Asian populations. The other reported differences in extent of disease at diagnosis by ethnicity.

Added value of this study

This is the first national-level whole of population evaluation of the burden of nasopharyngeal cancer in Aotearoa New Zealand describing incidence and survival outcomes. It finds that Aotearoa New Zealand has a distinct profile of nasopharyngeal cancer, with age, ethnicity and morphology among the main determinants of incidence and survival and highlights inequities, especially for Pacific peoples.

Implications of all the available evidence

Identification of the population groups most at risk of diagnosis with, and poor outcomes from, nasopharyngeal cancer provides direction for clinical practice changes to target those who could benefit most from early disease detection.

nasopharyngeal carcinoma, divided into differentiated and undifferentiated tumours, accounts for most cases in endemic parts of Asia, and is strongly associated with Epstein-Barr virus (EBV) infection. In contrast, keratinising squamous cell carcinoma of the nasopharynx accounts for less than 20% of cases worldwide and is relatively infrequent in endemic countries but often predominates in non-endemic regions and is associated with smoking. 1,4 Recent advances in the understanding of nasopharyngeal cancer risk factors and pathogenesis, and in the development of diagnostic and therapeutic technologies, have provided new opportunities for early detection and improved outcomes. The association of EBV viral and HLA host genotypes with increased susceptibility provide a basis for identifying individuals at high risk. 1 Plasma EBV DNA detection has shown promise for screening at risk populations for early detection of asymptomatic disease. 3 In established cases, plasma EBV DNA detection can aid risk stratification and monitoring of treatment response. 1 Optimisation of radiotherapy and chemotherapy protocols, such as with intensity modulated radiation therapy (IMRT) 9 and induction cisplatin-gemcitabine chemotherapy, 10 have improved locoregional control and overall survival and reduced toxicity. 5,11 In that context, there are currently few published data on demographic and clinical characteristics or the incidence of nasopharyngeal cancer at a national-level in Aotearoa New Zealand. 12 Previous research, limited to the Auckland region, reported that nasopharyngeal cancer disproportionately affects Maori, Pacific peoples and Asian populations 13,14 and reported on differences in extent of disease at diagnosis. 15 Ethnic diversification of Aotearoa New Zealand in recent decades coupled with advances in molecular detection, imaging techniques and optimised chemoradiation strategies underscores the importance of an updated review. Little is also known about survival outcomes for patients with nasopharyngeal cancer in Aotearoa New Zealand, and prognostic factors relevant to our population have not been defined.

As new diagnostic and therapeutic technologies have become available with the potential for earlier detection, more precise risk stratification and improved outcomes, it is important to acquire information about the current demographic profile, incidence and outcomes of nasopharyngeal cancer in the local population. Therefore, in the current study, we performed a review of 25 years of nasopharyngeal cancer registrations to describe its demographic profile, clinicopathological characteristics, incidence, time trends and survival outcomes in Aotearoa New Zealand between 1994 to 2018.

Methods

Study design and data source

We undertook a retrospective review of registrations of malignant neoplasms of the nasopharynx over a 25-year period from 1994 to 2018 in the New Zealand Cancer Registry (NZCR). The NZCR is the central repository for all new cancer diagnoses (excluding non-melanoma skin cancers) in Aotearoa New Zealand, as mandated by the Cancer Registry Act 1993. 16 We included all registrations of malignant neoplasms of the nasopharynx (ICD-7 code 146; ICD-8 code 147; ICD-9-CM code 147, ICD-10 code C11) between 1 January 1994 and 31 December 2018. Exclusion criteria included: date of diagnosis outside 1994-2018, no histological diagnosis, or recurrent disease including recurrent tumour at the site of previous nasopharyngeal cancer or new metastatic disease on the background of a previous nasopharyngeal cancer. Malignant neoplasms of soft tissue or minor salivary glands, melanoma and neuroendocrine tumours were excluded. Registrations with unknown ethnicity or domicile code were excluded. For survival analyses, cases diagnosed at death or post-mortem were excluded.
Registrations and variable selection
Individual level data for the following variables were extracted: diagnosis date (defined as the date of the first pathological report confirming nasopharyngeal cancer), cancer event ID (a unique registry entry code), age at diagnosis, sex, prioritised ethnicity, domicile code, morphological code, disease extent (NZCR extent of disease or The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) staging) and date of death. NZCR data were not independently verified (as this study was of de-identified data and did not include clinical notes review).

Demographic characteristics
Age at diagnosis was grouped into 10-29 years, 30-64 years and 54-94 years to form groups representing young, middle and older ages with sufficient numbers for analysis and aid comparison to previously published international data. Ethnicity was classified into Māori, Pacific, Asian or New Zealand European, and prioritized ethnicity was used if a registration listed multiple ethnicities (patients with more than one recorded ethnicity were allocated to a single ethnic group in order of priority: Māori, Pacific, Asian and New Zealand European).

Domicile codes were linked to District Health Boards (DHBs), and DHBs were grouped into one of four regions that corresponded to regional cancer networks, i.e. the Northern, Midland, Central and Southern regions. The Northern region covers the Northland, Auckland, Counties Manukau and WaiTamariki DHBs. The Midland region covers Waikato, Lakes, Bay of Plenty and Tairawhiti DHBs. The Central region covers Taranaki, Whanganui, MidCentral, Hawke’s Bay, Waikato, Lakes, Taranaki and Waitemata DHBs. The Southern region encompasses the whole of the South Island.

Domicile code was also used to assign deprivation level (a geographic area-based measure of deprivation coded 1-10 from areas of least to highest deprivation) using the NZDep index (NZDep91, NZDep96, NZDep2001, NZDep2006 and NZDep2013) from the same year that the NZCR would have been used for the domicile code. Deprivation level was grouped into NZDep 1-4, 5-7 and 8-10.

Registrations were grouped into three diagnostic time periods comprising approximately equal numbers of registrations. The earliest diagnostic period included registrations made between 28 January 1994 to 14 May 2003, the middle diagnostic period between 22 May 2003 to 8 March 2011 and the latest diagnostic period between 24 March 2011 to 19 December 2018.

Tumour characteristics
Morphology codes were classified into keratinising squamous cell carcinoma (KSCC) (ICD-O codes 8070 and 8071), differentiated non-keratinising carcinoma (DNKC) (ICD-O codes 8072 and 8073), undifferentiated non-keratinising carcinoma (UNKC) (ICD-O codes 8020, 8021, 8082, and 8083) and not otherwise specified (NOS) (ICD-O codes 8000 (neoplasm, malignant), as well as 8010 (carcinoma not otherwise specified)). Registrations without histological diagnosis may have been included in the NOS group.

Registrations up to 1997 were coded by NZCR extent of disease staging. These are 0 (in situ), 1 (localised), 2 (regional or node involvement), 3 (remote or diffuse metastases), or 5 (not stated). Registrations from 1998 onwards were coded with The National Cancer Institute’s SEER staging definitions. SEER codes are B (limited to organ of origin), C (extension to adjacent organs), D (extension to regional lymph nodes), E (distant metastases) and F (unknown). For analysis, NZCR and SEER coding were merged into three categories: NZCR 0, 1 and 2 with SEER B, C and D (‘local/regional’), NZCR 3 with SEER E (‘distant disease/metastatic’) and NZCR 5 with SEER F (‘unknown’).

Statistical analysis
Four patients, whose ethnicity was other than Asian, Pacific, Māori or New Zealand European, were removed from the final analysis. For the remaining registrations (n=577), the number and proportion of registrations were summarized by demographic (age, sex, ethnicity, deprivation, cancer region and diagnostic period) and pathological (morphological subtype and extent of disease) characteristics. Differences between groups were examined with Chi-squared tests with P values <0.05 being statistically significant.

Nasopharyngeal cancer incidence rates were calculated as the annual number of cases per 100,000 person-years, and presented for early, middle and late diagnostic periods, using the New Zealand resident population from the 1996, 2006 and 2013 censuses, respectively. Using the whole cohort, incidence rates were calculated for each age group (age-specific incidence rates). Age-standardised incidence rates were estimated by subgroups (morphology, sex and ethnicity), referencing the WHO world standard population. 95% confidence intervals were calculated. Differences in incidence rates between groups were regarded as being statistically significant when their 95% confidence intervals did not overlap.

For survival analyses, follow up time was calculated as the time from the diagnosis date to end of the study date (23 October 2019). Median follow up time was 12.5 years (range 0.84 – 25.7 years). Overall survival was calculated from the diagnosis date. Two patients with dates of death the same as their diagnosis date were excluded from the survival analysis. Patients with no known date of death were censored on the end of study date (23 October 2019). The Kaplan-Meier method was used to estimate the overall survival by age, sex,
ethnicity, morphology, disease extent and diagnostic period, and comparisons between survival curves were made with log rank tests. Five-year relative survivals were calculated as the ratio of the 5-year observed Kaplan-Meier survival to mean 5-year expected survival for the whole cohort and for each subgroup (age, sex, ethnicity, morphology, diagnosis period and disease extent). The expected survival was estimated by matching the individual patients to general population by age at diagnosis, birth year and sex using New Zealand population life tables. \(^{28}\) 95% confidence intervals of relative survival ratios were calculated. \(^{29}\)

Associations of survival outcomes with demographic and tumour characteristics were evaluated using univariable and multivariable Cox regression models to compute hazard ratios and 95% confidence intervals. Estimates were considered statistically significant for the values of \( P <0.05\). All data analyses were performed in Stata v16.1 and Microsoft Excel.

Ethics: This observational study of existing de-identified registry data was deemed not to require formal National Health and Disability Ethics Committee approval (out of scope for formal review). Local research institutional approval was granted by the Auckland DHB Research Review Committee (A+8707).

Results

Demographic and clinicopathological characteristics

A total of 615 registrations of malignant neoplasms of nasopharynx were made to the NZCR between 1st January 1994 and 31st December 2018 (Figure 1). After exclusion of 36 registrations of malignant neoplasms of soft tissue or minor salivary glands, melanoma or neuroendocrine tumours, 18 registrations with missing values, and 4 patients of ethnicity other than Asian, Pacific, Māori or New Zealand European, a cohort of 577 eligible patients remained with a median of 24 registrations per year (range 15–33) over the 25-year study period.

The demographic and clinicopathological characteristics of the retrospective cohort of 577 eligible patients are depicted in Table 1. The majority of cases (399/577, 69.2%) were diagnosed in the 30-64 year age group, with a median age at diagnosis of 54 years. 72.4% (418/577) Asian, 24.3% (140/577) New Zealand European, 25.3% (146/577) Pacific peoples and 13.6% (75/577) Māori. The majority of cases were the non-keratinising morphological subtypes (221/577 [38.3%] undifferentiated non-keratinising carcinoma or 87/577 [15.1%] differentiated non-keratinising carcinoma), while fewer were keratinising squamous cell carcinoma (133/577 [23.1%]) or the otherwise-specified morphological subtypes (116/577 [20.5%]). It was unknown how many of the NOS group had no histological diagnosis. Staging information was unknown for 48.2% (275/577) of cases.

Demographic factors varied between different nasopharyngeal cancer morphology subtypes (Table 1). Keratinising squamous cell carcinoma presented more frequently in the older (65–94 years) age group, in New Zealand European and Māori, outside of the Northern region, and in the earliest (1994–2003) diagnostic period. Differentiated non-keratinising and undifferentiated non-keratinising carcinomas presented more frequently in the middle (30–64 years) age group, in Pacific peoples and Asian, in the Northern region, and in the later (2011–2018) diagnostic period. See supplementary table 1 for a breakdown of characteristics by ethnicity.

Incidence

Overall, there was a crude incidence rate per 100,000 person-years of 0.58 (95% CI 0.57–0.58) compared to a WHO age-standardised incidence rate per 100,000 person-years of 0.49 (95% CI 0.45–0.53). For the cohort as a whole, there were no significant changes in crude (range 0.57 [95% CI 0.54–0.60] – 0.61 [95% CI 0.58–0.64]) or age-standardised (range 0.48 [95% CI 0.41–0.55] – 0.52 [95% CI 0.45–0.60]) incidence rates with time between the three diagnostic periods. Poisson regression resulted in a coefficient for diagnosis year of 0.01 (95% CI 0.01–0.02) supporting that the trend was stable. However, incidence rates varied markedly between different subgroups. By age (Figure 2 A), age-specific incidence rates were lowest in the younger (10–29 years) age group (0.1 [95% CI 0.09–0.1]), highest in the older (65–90 years) age-group (1.12 [95% CI 1.08–1.16]) and intermediate in the middle (30–64 years) age group (0.87 [95% CI 0.85–0.88]). With time, age-specific incidence rates increased in the younger (10–29 years) age group and decreased in the older (65–90) age group (Figure 2A). Males had higher age-standardised incidence (0.72 [95% CI 0.65–0.79]) than females (0.27 [95% CI 0.23–0.32]) (Figure 2C). By ethnicity (Figure 2D), Pacific peoples had the highest age-standardised incidence (3.43 [95% CI 2.85–4.01]), followed by Asian (2.77 [95% CI 2.38–3.16]) then Māori (0.74 [95% CI 0.56–0.92]), with the lowest rate in New Zealand European (0.17 [95% CI 0.14–0.20]). The incidence of nasopharyngeal cancer in different sex and ethnicity subgroups was largely unchanged with time except for a recent decrease in Asian patients. Among morphological subtypes, there were variable trends over time, with an increasing incidence of differentiated non-keratinising carcinoma, stable incidences of keratinising squamous cell carcinoma and undifferentiated non-keratinising carcinoma, and a decreasing incidence of nasopharyngeal cancer not-otherwise-specified.

Survival outcomes

Median follow up time was 12.5 years (range 0.84–25.7 years). For the cohort as a whole, median overall
survival was 9.3 years (95% CI 6.4-12.5 years) (Figure 3A). Kaplan–Meier and log-rank tests showed significant differences in overall survival by age (Figure 3B), ethnicity (Figure 3C), morphology (Figure 3D), and disease extent (Figure 3E). Overall survival was significantly longer in subgroups with younger age at diagnosis, Asian ethnicity, nasopharyngeal cancer morphologies other than keratinising squamous cell carcinoma, and locoregional or unknown disease extent. Conversely, overall survival was significantly shorter in subgroups with older age at diagnosis, non-Asian ethnicity, keratinising squamous cell carcinoma, and distant disease.

Five-year overall survival rate (Table 2), for the cohort as a whole, was 57.7% (95% CI 53.4-61.8) and the 10-year overall survival rate was 49.2% (95% CI 44.7-53.5). Five-year overall survival rates were higher for the younger (10–29 years) age group (86.6% [95% CI 70.8-94.2]) and lower for the older (65–94 years) age group (30.0% [95% CI 22.4-37.9]) compared to the middle

---

**Figure 1.** Flow diagram of the identification of eligible registrations.

* * 36 excluded registrations included adenoid cystic carcinoma10, adenocarcinoma, not otherwise specified4, malignant melanoma1, embryonal rhabdomyosarcoma, not otherwise specified3, neuroendocrine carcinoma, not otherwise specified2, papillary adenocarcinoma, not otherwise specified, clear chordoma, not otherwise specified1, small cell carcinoma, not otherwise specified1, cell adenocarcinoma, not otherwise specified1, rhabdomyosarcoma, not otherwise specified1, alveolar rhabdomyosarcoma1, cellular leiomyoma1, synovial sarcoma, biphasic1, oligodendroglioma, not otherwise specified1, ^ 18 excluded registrations included registrations of unknown ethnicity10, unknown domicile code10, # 4 excluded registrations with ethnicity other than Asian, Pacific, Māori or New Zealand European included Middle Eastern2, African1, Latin American/Hispanic1.
|                          | Total | Keratinising Squamous Cell Carcinoma | Differentiated Non-Keratinising Carcinoma | Undifferentiated Non-Keratinising Carcinoma | Not Otherwise Specified* | N  | %  | n  | %  | n  | %  | n  | %  | P** |
|--------------------------|-------|------------------------------------|------------------------------------------|---------------------------------------------|--------------------------|----|----|----|----|----|----|----|----|-----|
|                          | N     | %       | n          | %       | n          | %       | n          | %       | P** |
| Age                      |       |         |            |         |            |         |            |         |     |
| 10-29 y                  | 40    | 6.9     | 5          | 3.8     | 4          | 4.6     | 22         | 10.0    | <0.001 |
| 30-64 y                  | 399   | 69.2    | 83         | 62.4    | 69         | 79.3    | 166        | 75.1    | 0.460  |
| 65-94 y                  | 138   | 23.9    | 45         | 33.8    | 14         | 16.1    | 33         | 14.9    | 0.001  |
| Sex                      |       |         |            |         |            |         |            |         |     |
| Male                     | 418   | 72.4    | 94         | 70.7    | 67         | 77.0    | 164        | 74.2    | 0.684  |
| Female                   | 159   | 27.6    | 39         | 29.3    | 20         | 23.0    | 57         | 25.8    | 0.316  |
| Ethnicity                |       |         |            |         |            |         |            |         |     |
| NZ European              | 140   | 24.3    | 54         | 40.6    | 15         | 17.2    | 34         | 15.4    | <0.001 |
| Māori                    | 75    | 13.0    | 28         | 21.1    | 16         | 18.4    | 23         | 10.4    | 0.590  |
| Pacific                  | 146   | 25.3    | 27         | 20.3    | 23         | 26.4    | 62         | 28.1    | 0.027  |
| Asian                    | 216   | 37.4    | 24         | 18.1    | 33         | 37.9    | 102        | 46.2    | 0.419  |
| Deprivation              |       |         |            |         |            |         |            |         |     |
| NZDep 1-4                | 164   | 28.4    | 37         | 27.8    | 23         | 26.4    | 62         | 28.1    | 0.298  |
| NZDep 5-7                | 162   | 28.1    | 32         | 24.1    | 28         | 32.2    | 56         | 25.3    | 0.338  |
| NZDep 8-10               | 251   | 43.5    | 64         | 48.1    | 36         | 41.4    | 103        | 46.6    | 0.353  |
| Region                   |       |         |            |         |            |         |            |         |     |
| Northern                 | 326   | 56.5    | 44         | 33.1    | 55         | 63.2    | 141        | 63.8    | <0.001 |
| Midland                  | 85    | 14.7    | 37         | 27.8    | 8          | 9.2     | 27         | 12.2    | 0.060  |
| Central                  | 105   | 18.2    | 30         | 22.6    | 13         | 14.9    | 41         | 18.6    | 0.154  |
| Southern                 | 61    | 10.6    | 22         | 16.5    | 11         | 12.6    | 12         | 5.4     | 0.118  |
| Diagnosis period         |       |         |            |         |            |         |            |         |     |
| 1994-2003                | 192   | 33.3    | 54         | 40.6    | 8          | 9.2     | 53         | 24.0    | <0.001 |
| 2003-2011                | 192   | 33.3    | 41         | 30.8    | 21         | 24.1    | 91         | 41.2    | 0.287  |
| 2011-2018                | 193   | 33.5    | 38         | 28.6    | 58         | 66.7    | 77         | 34.8    | 0.147  |
| Disease extent           |       |         |            |         |            |         |            |         |     |
| Local/regional           | 212   | 36.7    | 49         | 36.8    | 40         | 46.0    | 85         | 38.5    | 0.060  |
| Distant/metastatic       | 87    | 15.1    | 22         | 16.5    | 10         | 11.5    | 26         | 11.8    | 0.213  |
| Unknown                  | 278   | 48.2    | 62         | 46.6    | 37         | 42.5    | 110        | 49.8    | 0.507  |

**Table 1: Demographic and clinicopathological characteristics of the Aotearoa New Zealand nasopharyngeal cancer cohort by morphological subtype.**

* including 74 registrations of “neoplasm, malignant” and 67 registrations of “carcinoma, not otherwise specified”.

** P values are from Chi squared tests.
(30–64 years) age group (64.3% [95% CI 59.2-69.0]). Five-year overall survival rates were higher for Asian (74.5% [95% CI 67.8-80.0]) than other ethnicities. Five-year overall survival rates were lower for keratinising squamous cell carcinoma (38.2% [95% CI 29.7-46.5]) than other nasopharyngeal cancer morphological subtypes. Five-year overall survival rates were lower for those with distant disease at diagnosis (36.2% [95% CI 26.0-46.4]) than for those with locoregional or unknown disease extent. These differences remained significant after calculation of relative 5-year survival rates (Table 2) that adjusted for expected background mortality by age and sex.

Factors associated with overall survival
Variables significantly associated with overall survival on univariable analysis (Table 3) were age, sex, ethnicity, deprivation, region, diagnostic period, morphology and disease extent. On multivariable analysis (Table 3), age, ethnicity, morphology, disease extent and diagnostic period remained independent and significant factors impacting on overall survival. Older age at diagnosis (HR=2.75 [95% CI 2.15-3.52]), Māori ethnicity (HR 2.21 [95% CI 1.46-3.36]), Pacific ethnicity (HR 2.10 [95% CI 1.50-2.92]), New Zealand European (HR 1.84 [95% CI 1.31-2.61]), keratinising squamous cell carcinoma (HR=1.72 [95% CI 1.27-2.33]) and distant disease (HR=1.74 [95% CI 1.25-2.40]) were associated with increased risk of death, whereas younger age at diagnosis (HR=0.30 [95% CI 0.14-0.63]), and earlier diagnostic period (1994-2003) (HR=0.74 [95% CI 0.56-0.97]) were associated with reduced risk of death. A global test for proportional hazards assumptions yielded \( p = 0.0001 \). We ran the Cox models separated by three defined periods (not reported), and the HRs in all three models remained similar to those in the main model. Therefore, we report the main model only.

Discussion
Our study provides the first national-level whole of population evaluation of the burden of nasopharyngeal cancer in Aotearoa New Zealand. Our results can be viewed in the context of current understanding of the distinct ethnic and geographic distribution of nasopharyngeal cancer globally as has been described by international data and previous studies from elsewhere.\(^1\) In Aotearoa New Zealand, it was known from annual reports from the NZCR\(^3\) that the incidence of nasopharyngeal cancer was low compared to other cancers, but the characteristics and outcomes of the patient population affected by nasopharyngeal cancer had not been described.
Figure 3. Overall survival from nasopharyngeal cancer in Aotearoa New Zealand. Survival curves are shown for the cohort as a whole (A), and by age at diagnosis (B), ethnicity (C), morphology (D) and disease extent (E) as the main determinants of overall survival.
Our study showed a distinct pattern of nasopharyngeal cancer in Aotearoa New Zealand compared to elsewhere. The overall incidence of nasopharyngeal cancer in Aotearoa New Zealand was low, with a median of 24 registrations per year, and age-standardised incidence rates per 100,000 person-years for men (0.72) and women (0.27) were consistent with international data from other non-endemic countries. However, unlike other countries, where the incidence of nasopharyngeal cancer is decreasing by approximately 1% per year,17 the age-standardised incidence rate of nasopharyngeal cancer in Aotearoa New Zealand remained unchanged over a 25-year period. In addition, we found significant ethnic disparities, with nasopharyngeal cancer age-standardised incidence rates that were 21-fold higher for those of Pacific ethnicity, 17-fold higher for Asian and 4-fold higher for Māori, compared to New Zealand European. This differs from previous data limited to the Auckland region that reported a higher nasopharyngeal cancer incidence in patients of Chinese rather than Pacific ethnicity.13 Importantly, this shows that in Aotearoa New Zealand, the greatest burden of nasopharyngeal cancer falls on patients of Pacific ethnicity. Other reports from elsewhere linked Asian and Pacific ethnicities together,30 which risked missing ethnic-specific differences when studying heterogenous groups in aggregate. To our knowledge, this is one of the first studies from a non-endemic region to have shown the incidence of nasopharyngeal cancer to be highest in a non-Asian ethnic group. Despite nasopharyngeal cancer being considered non-endemic in Aotearoa New Zealand, the majority of cases in our study were non-keratinising morphologies, which are the dominant subtypes in endemic areas and those associated with EBV infection.1,2 Unlike other non-endemic settings, such as the United States where keratinising squamous cell carcinoma often predominates,18,30,31 we found keratinising squamous cell carcinoma in only

| Absolute 5-year Overall Survival | Relative 5-year Overall Survival* |
|----------------------------------|----------------------------------|
| N | % (95% CI) | % (95% CI) |
|-----------------|-----------|-----------|
| Total | 577 | 57.7 (53.4-61.8) | 61.4 (57.1-65.7) |
| Age | | | |
| 10-29 years | 40 | 86.6 (70.8-94.2) | 86.9 (76.3-97.5) |
| 30-64 years | 399 | 64.3 (59.2-69.0) | 65.8 (61.0-70.6) |
| 65-94 years | 138 | 30.0 (22.4-37.9) | 37.0 (27.6-46.4) |
| Sex | | | |
| Male | 418 | 54.7 (49.6-59.6) | 58.8 (53.7-64.0) |
| Female | 159 | 65.4 (57.3-72.4) | 68.0 (60.3-75.7) |
| Ethnicity | | | |
| NZ European | 140 | 52.4 (43.6-60.4) | 59.1 (49.8-68.4) |
| Māori | 75 | 45.3 (33.5-56.3) | 47.8 (35.9-59.7) |
| Pacific | 146 | 44.8 (36.2-53.0) | 47.1 (38.6-55.6) |
| Asian | 216 | 74.5 (67.8-80.0) | 77.5 (71.4-83.5) |
| NZDep 1-4 | 164 | 68.3 (60.2-75.1) | 72.9 (65.3-80.6) |
| NZDep 5-7 | 162 | 59.9 (51.7-67.2) | 64.4 (56.3-72.5) |
| NZDep 8-10 | 251 | 49.7 (43.1-55.9) | 52.4 (45.9-59.0) |
| Region | | | |
| Northern | 326 | 59.1 (53.3-64.4) | 62.8 (57.1-68.5) |
| Midland | 85 | 48.6 (37.5-58.9) | 52.1 (40.7-63.5) |
| Central | 105 | 65.0 (54.4-73.7) | 67.6 (58.1-77.1) |
| Southern | 61 | 50.9 (37.5-62.8) | 56.5 (42.6-70.4) |
| Diagnosis Period | | | |
| 1994-2003 | 192 | 58.6 (51.3-65.2) | 63.6 (56.0-71.1) |
| Morphology | | | |
| KSCC | 133 | 38.2 (29.7-46.5) | 41.2 (32.3-50.1) |
| DNKC | 87 | 61.9 (48.8-72.5) | 64.6 (54.0-75.3) |
| UNKC | 221 | 67.6 (60.8-73.5) | 70.4 (64.0-76.8) |
| NOS | 136 | 57.4 (48.4-65.3) | 63.3 (54.1-72.5) |
| Disease extent | | | |
| Local/regional | 212 | 57.6 (50.4-64.2) | 60.8 (53.8-67.9) |
| Distant | 87 | 36.2 (26.0-46.4) | 39.1 (28.2-50.0) |
| Unknown | 278 | 64.5 (58.4-70.1) | 68.8 (62.8-74.8) |

Table 2: Five-year absolute and relative survival rates for the Aotearoa New Zealand nasopharyngeal cancer cohort as a whole, and for subgroups defined by age at diagnosis, ethnicity, morphology, disease extent and diagnosis period.

N, sample size; HR, CI, confidence intervals; KSCC, keratinising squamous cell carcinoma; DNKC, differentiated non-keratinising carcinoma; UNKC, Undifferentiated non-keratinising carcinoma; NOS, not otherwise specified.

* relative survival rates were adjusted for expected background mortality by age and gender.
23.1% of cases. Furthermore, the age-standardised incidence rates of keratinising squamous cell carcinoma and undifferentiated non-keratinising carcinoma in our study remained unchanged with time, unlike elsewhere, where significant time-dependent changes in rates of these morphology subtypes have been reported. Although this study demonstrated stable time trends and striking variation by ethnicity, it did not address factors underlying these distinct patterns of nasopharyngeal cancer incidence in Aotearoa New Zealand. In our study, the apparent increase over time in incidence of differentiated non-keratinising carcinoma and decrease in incidence of nasopharyngeal cancer not otherwise-specified may reflect changes in pathological practices for classifying nasopharyngeal cancer rather than real changes in disease incidence. As reported elsewhere, age and sex were also determinants of the nasopharyngeal cancer incidence in the Aotearoa New Zealand population. The higher registration count seen in the Northern region is likely due to the higher proportion of Asian and Pacific peoples domiciled in this part of Aotearoa New Zealand. Age, ethnicity and morphology were among the major determinants of overall survival in the Aotearoa New Zealand nasopharyngeal cancer cohort. The median overall survival of about 10 years and 5-year survival rate of about 60% was comparable to outcomes from other national population-based registry datasets. For example, the US National Cancer Institute reports a 5-year relative survival rate for all nasopharyngeal cancer stages combined of 61% compared to 61.4% in our study. The finding on multivariable analysis that age, ethnicity, morphology and disease extent all significantly impacted survival was also broadly consistent with international data. For example, the survival advantage of morphologies other than keratinising squamous cell carcinoma and for patients of Asian ethnicity compared to other ethnicities has also been reported elsewhere. Not only did Pacific peoples have the highest incidence of

| N | HR (95% CI) | P  | HR (95% CI) | P  |
|---|-------------|----|-------------|----|
| Age | 10-29 y | 40 | 0.31 (0.14-0.65) | 0.002 | 0.30 (0.14-0.63) | 0.002 |
|  | 30-64 y | 399 | 1.00 | Ref | 1.00 | Ref |
|  | 65-94 y | 138 | 3.21 (2.53-4.07) | <0.001 | 2.75 (2.15-3.52) | <0.001 |
| Sex | Male | 418 | 1.00 | Ref | 1.00 | Ref |
|  | Female | 159 | 0.72 (0.55-0.94) | 0.017 | 0.83 (0.63-1.10) | 0.201 |
| Ethnicity | NZ European | 140 | 2.23 (1.63-3.05) | <0.001 | 1.84 (1.31-2.61) | 0.001 |
|  | Māori | 75 | 2.55 (1.79-3.63) | <0.001 | 2.21 (1.46-3.36) | <0.001 |
|  | Pacific | 146 | 2.41 (1.77-3.28) | <0.001 | 2.10 (1.50-2.92) | <0.001 |
|  | Asian | 216 | 1.00 | Ref | 1.00 | Ref |
| Deprivation | NZDep 1-4 | 164 | 0.68 (0.51-0.90) | 0.008 | 0.93 (0.68-1.27) | 0.630 |
|  | NZDep 5-7 | 162 | 0.89 (0.68-1.16) | 0.390 | 1.02 (0.77-1.35) | 0.908 |
|  | NZDep 8-10 | 251 | 1.00 | Ref | 1.00 | Ref |
| Region | Northern | 326 | 1.00 | Ref | 1.00 | Ref |
|  | Midland | 85 | 1.48 (1.09-2.03) | 0.013 | 0.87 (0.60-1.26) | 0.449 |
|  | Central | 105 | 0.97 (0.71-1.33) | 0.856 | 0.89 (0.64-1.25) | 0.509 |
|  | Southern | 61 | 1.47 (1.04-2.10) | 0.031 | 1.12 (0.77-1.63) | 0.557 |
| Diagnosis Period | 1994-2003 | 192 | 0.88 (0.67-1.14) | 0.317 | 0.74 (0.56-0.97) | 0.031 |
|  | 2003-2011 | 192 | 1.00 | Ref | 1.00 | Ref |
|  | 2011-2018 | 193 | 0.71 (0.52-0.97) | 0.030 | 0.75 (0.55-1.04) | 0.082 |
| Morphology | KSCC | 133 | 2.13 (1.60-2.83) | <0.001 | 1.72 (1.27-2.33) | <0.001 |
|  | DNKC | 87 | 1.07 (0.71-1.59) | 0.757 | 0.96 (0.63-1.45) | 0.830 |
|  | UNKC | 221 | 1.00 | Ref | 1.00 | Ref |
|  | Other | 136 | 1.39 (1.03-1.88) | 0.031 | 1.26 (0.92-1.73) | 0.157 |
| Disease extent | Local/Regional | 212 | 1.00 | Ref | 1.00 | Ref |
|  | Distant | 87 | 1.92 (1.39-2.63) | <0.001 | 1.74 (1.25-2.40) | 0.001 |
|  | Unknown | 278 | 0.93 (0.72-1.20) | 0.592 | 0.92 (0.71-1.20) | 0.543 |

Table 3: Univariable and multivariable analysis of factors associated with overall survival (measured as mortality HR, hazard ratios) of the Aotearoa New Zealand nasopharyngeal cancer cohort.

N, sample size; HR, CI, confidence intervals; KSCC, keratinising squamous cell carcinoma; DNKC, differentiated non-keratinising carcinoma; UNKS, Undifferentiated non-keratinising carcinoma; NOS, not otherwise specified.
nasopharyngeal cancer, but their survival outcomes were numerically the poorest out of any ethnic group in our study. The lack of detailed information about clinical stage at presentation or subsequent access to treatment, hindered further investigation into reasons behind those poor outcomes for Pacific patients. Age at diagnosis has consistently been found to be associated with survival outcomes in population-based studies of nasopharyngeal cancer. In our study, age was the strongest prognostic factor with approximately 3-fold increases or decreases in risk of death in the youngest and oldest age groups, respectively, compared to the middle-age group. Survival outcomes were not significantly improved in the most recent diagnostic period, despite introduction of newer radiation therapy techniques, combined modality treatment protocols and other improvements in clinical practice. As expected survival outcomes were poorer in patients presenting with distant disease. In support of targeted screening for at risk Pacific peoples, the age-standardised incidence rate per 100,000 person-years of 3.43 for Pacific peoples in Aotearoa New Zealand was similar to that reported from high-risk geographical regions elsewhere, such as Thailand (2.1) and Philippines, Manila (3.3), but lower than in Singapore (7.1) and Hong Kong (9.5).

The findings of the current study have implications for the development of healthcare policy and clinical practice changes to address the poor outcomes and inequities caused by nasopharyngeal cancer in Aotearoa New Zealand. The finding that advanced disease at diagnosis is a strong adverse prognostic factor highlights the potential importance of earlier detection. Currently, there is no targeted screening program for nasopharyngeal cancer in Aotearoa New Zealand. However, plasma EBV DNA analysis was shown to be a potentially useful screening test for detecting early stage asymptomatic nasopharyngeal cancer in an at risk population in Hong Kong with 97.1% sensitivity and 98.6% specificity. Clinical practice guidelines now recommend screening of high risk populations. Plasma EBV testing is not yet widespread or common practice for early detection of nasopharyngeal cancer. Its adoption will need to consider the costs and organisation required, as well as defining the target group for screening. There is now a particular need to consider the feasibility of targeted screening in the Aotearoa New Zealand context. Based on the findings of this study, targeted screening could perhaps be best considered for Pacific patients who have the highest incidence and poorest outcomes from nasopharyngeal cancer in Aotearoa New Zealand.

This study had a number of strengths and limitations, inherent in the data used. As the data is based on a legally-mandated national cancer registry, with international standards of completeness and quality control, the study population was fully representative as it comprised all nasopharyngeal cancer registrations made in Aotearoa New Zealand over 25 years. The dataset had nearly complete demographic and mortality data. However, the variables available for analysis were limited to those collected routinely during the process of cancer registration. Therefore, clinical staging information was unavailable and registry-based stage categorization based on pathology reports were available for only about half of the registrations. Moreover, the national registry does not include detailed treatment or clinical management information, or outcomes other than mortality. EBV tumour status was not available in the registry dataset. These limitations meant that we could not evaluate cancer-specific survival, distant metastasis-free survival or relapse-free survival, relapse patterns, or short-term and long-term treatment related complications, such as stroke, radiation-associated second malignancies and aspiration pneumonia. We could not assess treatment, such as types of radiation used. The addition of EBV status in the NZCR would be optimal given the modern understanding of its role as an aetiological factor and prognostic and predictive biomarker.

In conclusion, our study has shown a distinct profile of nasopharyngeal cancer in Aotearoa New Zealand. Age, ethnicity and morphology were among the main determinants of variations in nasopharyngeal cancer incidence and survival outcomes in Aotearoa New Zealand. In the future, collection of prospective data, including EBV tumour status, clinical stage, treatment information and nasopharyngeal cancer specific outcomes could aid further understanding of the epidemiology of nasopharyngeal cancer in Aotearoa New Zealand. Identification of population groups most at risk of nasopharyngeal cancer and locally-relevant prognostic factors could guide new healthcare policy development and clinical practice changes to improve disease prevention and care for those most in need.

Contributors
Alice Minhinnick: conceptualisation, data curation, investigation, methodology, project administration, writing (original draft), writing (review & editing). Phyu Aye: formal analysis, methodology, visualisation, writing (original draft, review & editing). Mark Elwood: supervision, writing (review & editing). Mark McKeage: conceptualisation, formal analysis, methodology, supervision, visualisation, writing (original draft, writing (review & editing).

Data sharing statement
The data for this study were provided by the New Zealand Ministry of Health, and may be available to other researchers who meet data access requirements. Please contact data_enquiries@moh.govt.nz for further details on eligibility and data provision.

Declaration of interests
The authors have no conflicts to disclose.
Acknowledgement
No.

Funding
No external funding.

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.lanwpc.2022.100522.

References
1. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. *Lancet*. 2019;394:54–56.
2. Chang ET, Ye W, Zeng YY, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. *Cancer Epidemiol Biomarkers Prev*. 2021;30:1035–1047.
3. Ministry of Health. New cancer registrations 2017. Wellington: 2019; [cited 2022 Feb 20]. Available from: https://www.health.govt.nz/publication/new-cancer-registrations-2017.
4. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin*. 2013;63:8–53.
5. Tang LL, Chen WQ, Xue WQ, et al. Global trends in incidence and mortality of nasopharyngeal carcinoma. *Cancer Lett*. 2016;374:2–10.
6. Matsuda T, Won YJ, Chun-yu Chiang R, et al. Rare cancers are not rare in Asia as well: the rare cancer burden in East Asia. *Cancer Epidemiol*. 2020;67:101702. Available from: https://www.sciencedirect.com/science/article/pii/S1579727419301660.
7. Statistics New Zealand. New Zealand’s population reflects growing diversity 2019. 2019; [cited 2022 Feb 20]. Available from: https://www.stats.govt.nz/news/new-zealands-population-reflects-growing-diversity.
8. Chan KCA, Woo JKS, King A, et al. Analysis of plasma Epstein–Barr virus DNA to screen for nasopharyngeal cancer. *N Engl J Med*. 2017;377:753–752.
9. Zhang B, Mo Z, Du W, Wang Y, Liu L, Wei Y. Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: a systematic review and meta-analysis. *Oral Oncol*. 2015;51:1041–1046.
10. Zhang Y, Chen H, Lu G-Q, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. *N Engl J Med*. 2019;381:1124–1133.
11. Cao SM, Yang Q, Guo L, et al. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in regionally advanced nasopharyngeal carcinoma: a phase III multicentre randomised controlled trial. *Eur J Cancer*. 2017;75:14–23.
12. Cox B, Taylor K. Treasure E. Trends in oral cancer by subsite in New Zealand. *Eur J Cancer Part B Oral Oncol*. 1995;31:113–117.
13. Morton RP, Benjamin CS. Nasopharyngeal carcinoma in Auckland: a study of racial factors. *Australas Radiol*. 1995;39:147–151.
14. Popat SR, Laravg PG, Morton R, McFerron N, Irsh J, Freeman JL. Epstein Barr virus genome in nasopharyngeal carcinomas from New Zealand. *Head Neck*. 2000;22(5):505–508.
15. Ianovski I, Izzard M, Morton RP, Plank LD. Nasopharyngeal carcinoma: Differences in presentation between different ethnicities in the New Zealand setting. *ANZ J Surg*. 2012;82(4):254–257.
16. Ministry of Health. New Zealand Cancer Registry [Internet]. 2019. Wellington: Available from: https://www.health.govt.nz/nz-health-statistics/national-collections-and-surveys/collections/new-zealand-cancer-registry-nzcr. Accessed 23 October 2019.
17. Tse IA, ITS Yu, Mang OWK, Wong SL. Incidence rate trends of histological subtypes of nasopharyngeal carcinoma in Hong Kong. *Br J Cancer*. 2006;95(9):1269–1271.
18. Ou SHI, Zell JA, Ziegas A, Anton-Culver H. Epidemiology of nasopharyngeal carcinoma in the United States: Improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. *Ann Oncol*. 2007;18(1):20–35.
19. American Cancer Society. Survival rates for nasopharyngeal cancer [Internet]. [cited 2022 Feb 20]. Available from: https://www.cancer.org/cancer/nasopharyngeal-cancer/detection-diagnosis-stage/survival-rates.html.
20. Zhu Y, Song X, Li R, Quan H, Yan L. Assessment of nasopharyngeal cancer in young patients aged ≤30 years. *Front Oncol*. 2019;9:1797.
21. Ministry of Health. HISO 2001: 2017. Ethnicity Data Protocols. Ministry of Health Wellington; 2017.
22. Atkinson J, Salmond C, Crampton P. NZNDE2013 Index of Deprivation. Wellington: University of Otago; 2014.
23. Statistics New Zealand. IDI Data Dictionary: Cancer Registrations Data. February 2017 Ed. Wellington: Stats NZ; 2017.
24. Schmoll H-J. AJCC Cancer Staging Manual. 6th Ed. Annals of Oncology; 2003.
25. NZ Stats. 2006 Census [Internet]. Available from: http://zzz.dotstat.stats.govt.nz/wbos/index.aspx.
26. Ahmed OB, Boschi-pinto C, Lopez AD. Age standardization of rates: a new WHO standard. *GPE Discussion Pap Ser*. 2004;3:1–14.
27. Boyle P, Parkin D. Statistical methods for registries. *Cancer Regist Princ Methods*. 1991;95:246–258.
28. StatsNZ. New Zealand cohort life tables: 2021 update [Internet]. [cited 2022 Feb 20]. Available from: https://www.stats.govt.nz/information-releases/new-zealand-cohort-life-tables-march-2021-update.
29. Parkin DM, Hakulinen T. Cancer registration: principles and methods. Analysis of survival. *IARC Sci Publ*. 1993;153:159–176.
30. Argirion I, Zarins KR, Ruterbusch J, et al. Increasing incidence of Epstein–Barr virus–related nasopharyngeal carcinoma in the United States. *Cancer*. 2010;126:121–130.
31. Arnold M, Wilde-Robinson MA, Visser O, et al. Lower mortality from nasopharyngeal cancer in the Netherlands since 1970 with differential incidence trends in histopathology. *Oral Oncol*. 2015;49:237–243.
32. Bray F, Haugen M, Moger TA, Treidl S, Aalen OØ, Grotmol T. Age incidence curves of nasopharyngeal carcinoma worldwide: Bimodality in low-risk populations and aetiologic implications. *Cancer Epidemiol Biomarkers Prev*. 2008;17:2356–2365.
33. Ruuskanen M, Grenman R, Leivo I, et al. Outcome of nasopharyngeal carcinoma in Finland: a nationwide study. *Acta Oncol (Madr)*. 2018;57:251–256.
34. Wu SG, Liao XL, He ZY, et al. Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: a population-based analysis. *Oral Oncol*. 2017;73:83–87.
35. Bossi P, Chau AT, Lacita L, et al. Nasopharyngeal carcinoma: ESMO–EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2021;32:452–465.